Trillium Therapeutics Inc (TRIL)

[NY1972]

CUDC-907 Decreases MYC Protein Levels in DLBCL Cells

Forty-four of the 57 patients included in the ASCO presentation were evaluable for response assessment per protocol. Of the 16 patients with DLBCL enrolled across the dose escalation and expansion phases of the study, 10 were evaluable for disease response at the time of data cut-off. The best responses observed in these patients were CR (2 patients), PR (4 patients) SD (2 patients) and progressive disease, or PD (2 patients), with median duration on treatment of 3 months (range: 1.4-24.2 months, ongoing). The overall median duration on treatment for these 16 patients was 50 days. Objective responses were observed in patients with different subtypes of DLBCL, including germinal center B cell lymphoma (GCB) as well as in 3 patients with t-FL/ DLBCL.

http://files.shareholder.com/downloads/ABEA-5QPVEJ/1856031492x0x866770/1570539B-E9F4-4850-A175-139B5342E0A3/ASH2015CUDC-907.pdf